Nobivac®

Canine 1-DAPPv

A proven foundation for vaccine protocols. Canine 1-DAPPv is a combination vaccine approved for protection against canine distemper virus, adenovirus type 1 and 2, canine parainfluenza virus, and canine parvovirus.

AH Vaccine Clamshell Tray 2020 Nobivac

CANINE 1-DAPPV PROVIDES PROTECTION AGAINST:

Canine Distemper Virus, Canine Adenovirus 2, Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses).

  • Protects against all known strains of CPV, including CPV-2c2,3
  • High antigenic mass (titer), low passage parvovirus vaccine
  • Canine vaccine containing CPV-2b, one of the most prevalent field strains of parvovirus
  • Protects against 2 types of adenovirus that cause hepatitis and respiratory disease in dogs
  • Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1 and 2, parainfluenza and parvovirus in 1 formula
  • First to publish data showing protection against CPV-2c challenge2
  • Multiple studies demonstrate the ability to override maternal antibodies1

INDICATIONS:

An aid in the prevention of disease caused by canine distemper virus, adenovirus type 1 (hepatitis) and adenovirus type 2 (respiratory disease), canine parainfluenza virus, and canine parvovirus.

Recommended for use in healthy dogs 6 weeks of age or older.

ADMINISTRATION AND DOSAGE

  • Subcutaneous or intramuscular injection
  • Primary vaccination may begin as early as 6 weeks
  • Repeat at 2 to 4 week intervals until the dog is 12 weeks of age
  • Annual revaccination with 1 dose is recommended
  • Available in a 25 x 1 mL dose presentation

Efficacy & Comparisons

NOBIVAC® CANINE 1-DAPPV—A PROVEN FOUNDATION FOR VACCINE PROTOCOLS

D–CANINE DISTEMPER VIRUS (CDV)

  • Onderstepoort-type strain in Nobivac® vaccines provides a high level of safety1

A–CANINE ADENOVIRUS TYPE 2 (CAV-2)

  • Protection against CAV-1 and CAV-2 without the side effects associated with modified live CAV-1 vaccines4

P–CANINE PARAINFLUENZA VIRUS (CPIV)

  • Systemic administration stimulates a strong IgG response1

PROTECT AGAINST ALL KNOWN STRAINS OF CANINE PARVOVIRUS (CPV), INCLUDING CPV-2C

PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ2

  • No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains2
  • First published data showing protection against CPV-2c challenge2
  • All vaccinated puppies were protected from disease
  • All control puppies developed disease and 50% died or were euthanized

No items to show.

Loading…

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

AAHA Canine Vaccination Guidelines

In-depth information about canine vaccinations and veterinary best practices.

Download

Nobivac® Social Media Kits

Digital Assets

Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.

Download

Quick Guide to Lepto

eBook

A handy guide to protect dogs and prevent the spread of leptospirosis.

Download

No items to show.

Loading…

References:

1. Data on file, Merck Animal Health. 

2. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101. 

3. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108. 

4. Greene C, Rupprecht C. Rabies and other lyssavirus infections. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. St. Louis, MO: Saunders/Elsevier; 2006:167–183. 

7. Cornell University College of Veterinary Medicine; American Association of Feline Practitioners. Feline leukemia virus. Available at: http://www.vet.cornell.edu/fhc/brochures/felv.html . Accessed December 29, 2011. 

8. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1-2) :48-55.

View All Nobivac References